Facebook
Twitter
LinkedIn
ForwardMiami Cancer Institute Brain Glioblastoma Update
Glioblastoma is the most common and aggressive primary brain tumor. This course includes expert faculty, Antonio Chiocca, M.D., Ph.D. and Zhijian Chen, M.D., Ph.D., who discuss the complexity of GBM necrosis/hypoxia and angiogenesis, personalized medicine, and navigate through complex cases and novel treatment strategies.
Topics within this module include:
- Clinical Trials of Surgical Immunotherapy for Glioblastoma
- Hypoxia and Glioblastoma
Target Audience
Neurologists, Medical Oncologists, Neurosurgeons, Neuro-Oncologists, Medical Oncologists, Neuroradiologists, Diagnostic Radiologists, Radiation Oncologists, Emergency Medicine Physicians, Pathologists, Neuroscience Nurses, Neurosurgery Nurses, Advanced Practice Registered Nurses, Clinical Pharmacists, Respiratory Therapists, Pharmacy Technicians and Physician Assistants/Physician Associates, as well as other specialists interested in the fields of neuro-oncology and neuroscience.
Learning Objectives
- Identify the central necrosis/hypoxia as the pathognomonic hallmark of glioblastoma.
- Examine the mechanism behind the central necrosis/hypoxia phenomenon and explore the angles to intervene that can lead to new therapy.
- Recognize the controversies of implementing tumor treating fields for glioblastoma.
Antonio Chiocca, M.D., Ph.D.
Chair, Department of Neurosurgery
Co-director, Institute for the Neurosciences
Harvey W. Cushing Professor of Neurosurgery
Harvard Medical School
Cambridge, Massachusetts
Zhijian Chen, M.D., Ph.D.
Neuro-oncologist
Miami Cancer Institute
Baptist Health South Florida
Miami, Florida
Antonio Chiocca, M.D., Ph.D., faculty for this educational activity, is an advisor with Insightec, DNAtrix, Bionaut Therapeutics and Synthetic Biologics. He has equity interest in DNAtrix, Seneca Therapeutics and Ternalys Therapeutics. He is named inventor on patents related to oncolytic HSV1 (licensed to Candel Therapeutics) Royalties to MassGeneral Brigham from Candel Therapeutics and noncoding RNA’s. He is the founder of Ternalys Therapeutics. He has indicated that the presentation or discussion will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Zhijian Chen, M.D., Ph.D., faculty for this educational activity, has no relevant financial relationships with ineligible companies* to disclose, and has indicated that the presentation or discussion will not include off-label or unapproved product usage.
Manmeet Ahluwalia, M.D., conference director for this educational activity, is a researcher for AstraZeneca, Bayer, Bristol Myers Squibb, Incyte, Merck, Mimivax, Novocure and Pharmacyclics. He is a consultant for Apollomics, Bayer, Caris Life Sciences, Cellularity, GSK, Insightec, Janssen, Kiyatec, Novocure, Prelude, Pyramid Biosciences, SDP Oncology, Tocagen, Viewray, Voyager Therapeutics, Xoft, Varian Medical System, Nuvation, aAnheart Therapeutics, Theraguix and CAIRIN Therapeutics. He has individual stocks/stock options with Cytodyn, Medinnovate Advisors LLC, and Mimivax. He has indicated that the presentation or discussions will not include off-label or unapproved product usage. All of the relevant financial relationships listed for this individual have been mitigated.
Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.
*Ineligible companies ― Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
Baptist Health South Florida designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 2.00 AMA PRA Category 1 Credit™
- 2.00 General certificate of attendance
- 2.00 Nurse Practitioners
- 2.00 Florida Board of Nursing
- 2.00 Florida Board of Pharmacy
- 2.00 Florida Board of Respiratory Therapy
Price
Required Hardware/Software
 | PC/Mac UsersThis site is supported on the most recent stable releases of the following browsers:
| ||||||
 | Mobile UsersThis site is supported on the following mobile devices:
| ||||||
 | Technical SupportIf you are experiencing technical difficulties or have received an error message, please send an email to CME@baptisthealth.net and include a print screen of the error message, your browser name and version, username and URL where the error occurred. You can expect a response within 48 hours. |
